Doublet – Breast Cancer: Initiate 2L pivotal study of RLY-2608 + fulvestrant in 2025, pending regulatory discussions; Triplets – Breast Cancer: Report initial safety data for RLY-2608 + ribociclib + fulvestrant in the fourth quarter of 2024; Initiate RLY-2608 + ribociclib + fulvestrant triplet dose expansion cohort in the first half of 2025; Initiate RLY-2608 + atirmociclib (CDK4) + fulvestrant triplet by the end of 2024; Monotherapy – Solid Tumors: Initiate RLY-2608 monotherapy solid tumor dose expansion cohort by the end of 2024. Monotherapy – Vascular Malformations: Initiate vascular malformations study in the first quarter of 2025
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RLAY:
- Relay Therapeutics announces interim data for RLY-2608
- Relay Therapeutics Announces Positive Interim Data for RLY-2608 Demonstrating Clinically Meaningful Progression Free Survival
- Relay Therapeutics Announces Webcast to Report RLY-2608 Data on September 9, 2024
- Relay Therapeutics price target lowered to $24 from $25 at Oppenheimer
- Relay Therapeutics reports Q2 EPS (69c), consensus (73c)